Summary:
Nordic Bioscience’s PRO-C3 test, now launched globally by Roche Diagnostics on cobas analyzers, offers a validated and CE-approved method to assess liver fibrosis severity using the Elecsys platform.

Takeaways:

  1. The PRO-C3 biomarker, now CE-approved and globally available via Roche’s cobas analyzers, aids in evaluating liver fibrosis using the ADAPT formula.
  2. The test has been clinically validated in Nordic Bioscience’s certified lab and backed by over 250 scientific publications.
  3. This marks the first product of a collaboration between Nordic Bioscience and Roche, highlighting a significant step in precision medicine for fibrotic diseases.

Nordic Bioscience announces that its PRO-C3 test has been launched by Roche Diagnostics on their cobas analyzers. The Roche Elecsys PRO-C3, used with the ADAPT formula (age, diabetes status, PRO-C3, platelets), assesses liver fibrosis severity, a disease responsible for approximately one in every 25 deaths worldwide.

PRO-C3 Biomarker Is Already Validated

The Nordic PRO-C3 biomarker is already validated in Nordic Bioscience CAP-CLIA certified laboratory in Denmark. This demonstrates that Nordic Bioscience is dedicated to helping patients in a precision medicine driven approach, and our Platform provides the quality needed for regulatory approval.

More than 250 Scientific Papers Published

Nordic Bioscience’s scientists have over that last 10 years published more than 250 scientific papers on the biomarker making us the leading place for research within PRO-C3 and fibrotic related diseases.  

The biomarker is the first from Nordic Bioscience’s fibrosis panel which has been CE-approved; 40% of deaths in the western world are associated with alterations of organs such as the liver, and we provide the tools to quantify this.  These are the tools of modern clinical chemistry.

“The Elecsys PRO-C3 test is the first test launched from the collaboration between Nordic Bioscience and Roche Diagnostics. We are proud that our technology becomes globally available to make a difference for patients,” says Morten Karsdal, CEO of Nordic Bioscience.  

Featured Image: Nordic Bioscience’s Roche cobas e 801 platform. Image: Nordic Bioscience